DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Merck & Co., Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

254 Comunicados de prensa

Ver todos los comunicados de prensa
13/11/2026
Industria
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Infancia
Medicina - Varios
Biotecnología
Salud
Ir de compras
Farmacéutica
Sanidad
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
13/11/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
12/11/2026
Eventos
Web y redes sociales
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Merck to Participate in the Jefferies Global Healthcare Conference in London
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
09/11/2026
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
03/11/2026
Industria
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
02/11/2026
Web y redes sociales
Eventos
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Biotecnología
Medicina - Varios
Farmacéutica
Salud
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
29/10/2026
Veterinaria
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Medicina - Varios
Cardiología
Biotecnología
Salud
Farmacéutica
Oncología
Web y redes sociales
Telefonía
Mercado de valores
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
26/10/2026
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
26/10/2026
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Ferias y Congresos
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0
22/10/2026
Ciencia
Medicina - Varios
Sanidad
Biotecnología
Farmacéutica
Salud
Oncología
Eventos
Industria
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Fuente
Merck & Co., Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0